News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia


(March 20, 2018) - Adamas Pharmaceuticals announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, were published online in CNS Drugs. Read more